Cholangiocarcinoma: early detection and screening in high-risk population

Abstract

Cholangiocarcinoma (CCA) is a highly lethal malignancy that comprises approximately 15% of all the primary liver tumors and 3% of gastrointestinal cancers. Diagnosis is often done when the disease is already at advanced stages, resulting in poor outcomes. Prevention of risk factors and early diagnosis are the cornerstones for improving survival. Early diagnosis is feasible in the setting of surveillance programs in patients at high risk of CCA such as patients with primary sclerosing cholangitis. Regrettably, surveillance of CCA in this population is hampered by the low diagnostic accuracy of current tumor markers at earlier stages, the difficulties of imaging techniques for the differential diagnosis between benign and malignant biliary strictures, and the need for invasive procedures for diagnostic confirmation. In this review we discuss the rationale for surveillance of CCA in high-risk populations, particularly patients with primary sclerosing cholangitis, the recommended tools for surveillance and diagnostic work-up, and future perspectives.

Keywords

Surveillance / cholangiocarcinoma / primary sclerosing cholangitis / magnetic resonance / tumor biomarker

References

[1] Banales JM,Lamarca A.Cholangiocarcinoma 2020: the next horizon in mechanisms and management.Nat Rev Gastroenterol Hepatol2020;17:557-88 PMCID:PMC7447603

[2] Brindley PJ,Ilyas SI.Cholangiocarcinoma.Nat Rev Dis Primers2021;7:65 PMCID:PMC9246479

[3] Forner A,Rengo M,Ponz-Sarvisé M.Clinical presentation, diagnosis and staging of cholangiocarcinoma.Liver Int2019;39 Suppl 1:98-107

[4] Izquierdo-Sanchez L,La Casta A.Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry.J Hepatol2022;76:1109-21

[5] Díaz-González Á.Surveillance for hepatocellular carcinoma.Best Pract Res Clin Gastroenterol2016;30:1001-10

[6] Sherman M.How to improve HCC surveillance outcomes.JHEP Rep2019;1:460-7 PMCID:PMC7005767

[7] Sherman M.Surveillance for hepatocellular carcinoma.Best Pract Res Clin Gastroenterol2014;28:783-93

[8] Wilson JMG,Organization WH. Principles and practice of screening for disease. 1968.

[9] Shieh Y,Sawaya GF,Kramer BS.Population-based screening for cancer: hope and hype.Nat Rev Clin Oncol2016;13:550-65 PMCID:PMC6585415

[10] Weismüller TJ,Bergquist A.International PSC Study GroupPatient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis.Gastroenterology2017;152:1975-1984.e8 PMCID:PMC5546611

[11] Fung BM.Cholangiocarcinoma in patients with primary sclerosing cholangitis.Curr Opin Gastroenterol2020;36:77-84

[12] Boonstra K,van Erpecum KJ.EpiPSCPBC Study GroupPopulation-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis.Hepatology2013;58:2045-55

[13] Burak K,Pasha TM,Petz J.Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis.Am J Gastroenterol2004;99:523-6

[14] Fevery J,Van Oirbeek R.Malignancies and mortality in 200 patients with primary sclerosering cholangitis: a long-term single-centre study.Liver Int2012;32:214-22

[15] Boonstra K,Ponsioen CY.Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review.J Hepatol2012;56:1181-8

[16] Khan SA,Brandi G.Cholangiocarcinoma: Epidemiology and risk factors.Liver Int2019;39 Suppl 1:19-31

[17] Boberg KM,Mitchell S.Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation.Scand J Gastroenterol2002;37:1205-11

[18] Villard C,Nilsson E.Population-based prospective surveillance of patients with primary sclerosing cholangitis (PSC) for early detection of cholangiocarcinoma.Hepatology2021;74:91A-92A

[19] Ali AH,Nasser-Ghodsi N.Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis.Hepatology2018;67:2338-51

[20] Bowlus CL,Lindor KD.AGA Clinical Practice Update on Surveillance for Hepatobiliary Cancers in Patients With Primary Sclerosing Cholangitis: Expert Review.Clin Gastroenterol Hepatol2019;17:2416-22

[21] Rizvi S,Gores GJ.Primary Sclerosing Cholangitis as a Premalignant Biliary Tract Disease: Surveillance and Management.Clin Gastroenterol Hepatol2015;13:2152-65 PMCID:PMC4618039

[22] Eaton JE,Bakhshi Z.Early Cholangiocarcinoma Detection With Magnetic Resonance Imaging Versus Ultrasound in Primary Sclerosing Cholangitis.Hepatology2021;73:1868-81 PMCID:PMC8177077

[23] Satiya J,Gupta K.Diagnostic yield of magnetic resonance imaging for cholangiocarcinoma in primary sclerosing cholangitis: a meta-analysis.Clin Exp Hepatol2020;6:35-41 PMCID:PMC7062114

[24] Venkatesh SK,Miller FH.IPSCSGReporting standards for primary sclerosing cholangitis using MRI and MR cholangiopancreatography: guidelines from MR Working Group of the International Primary Sclerosing Cholangitis Study Group.Eur Radiol2022;32:923-37

[25] Schramm C,Ringe KI,Yamamura J.MRI working group of the IPSCSGRecommendations on the use of magnetic resonance imaging in PSC-A position statement from the International PSC Study Group.Hepatology2017;66:1675-88

[26] Khoshpouri P,Hazhirkarzar B.Imaging Features of Primary Sclerosing Cholangitis: From Diagnosis to Liver Transplant Follow-up.Radiographics2019;39:1938-64

[27] Chapman MH,Bannoo S,Wittmann J.Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis: a 25-year single-centre experience.Eur J Gastroenterol Hepatol2012;24:1051-8 PMCID:PMC3584158

[28] Rudolph G,Klöters-Plachky P,Rost D.Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis.J Hepatol2009;51:149-55

[29] Janse M,Verdonk RC.IBD is associated with an increase in carcinoma in PSC irrespective of the presence of dominant bile duct stenosis.J Hepatol2012;57:473-4; author reply 475

[30] Eaton JE,Gores GJ.Biliary multifocal chromosomal polysomy and cholangiocarcinoma in primary sclerosing cholangitis.Am J Gastroenterol2015;110:299-309 PMCID:PMC4349337

[31] Hilscher MB,Carey EJ,Lindor KD.Dominant strictures in primary sclerosing cholangitis: A multicenter survey of clinical definitions and practices.Hepatol Commun2018;2:836-44 PMCID:PMC6049068

[32] Charatcharoenwitthaya P,Halling KC.Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis.Hepatology2008;48:1106-17

[33] Lindor KD,Harrison ME.American College of GastroenterologyACG Clinical Guideline: Primary Sclerosing Cholangitis.Am J Gastroenterol2015;110:646-59; quiz 660

[34] Levy C,Angulo P,Larusso N.The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis.Dig Dis Sci2005;50:1734-40

[35] Sinakos E,Keach J,Lindor KD.Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma.Clin Gastroenterol Hepatol2011;9:434-9.e1

[36] Björnsson E,Olsson R.CA 19-9 and CEA are unreliable markers for cholangiocarcinoma in patients with primary sclerosing cholangitis.Liver1999;19:501-8

[37] Ramage JK,Farrant J,Williams R.Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis.Gastroenterology1995;108:865-9

[38] Hultcrantz R,Danielsson Å.A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis.Journal of Hepatology1999;30:669-73

[39] Association for the Study of the Liver. Electronic address: [e-mail]., European Association for the Study of the Liver. EASL Clinical Practice Guidelines on Sclerosing Cholangitis.J Hepatol2022:S0168-8278(22)00326

[40] Aabakken L,Albert J.Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline.Endoscopy2017;49:588-608

[41] Gotthardt DN,Klöters-Plachky P,Stiehl A.Endoscopic dilation of dominant stenoses in primary sclerosing cholangitis: outcome after long-term treatment.Gastrointest Endosc2010;71:527-34

[42] Chapman MH,Hirschfield GM.British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis.Gut2019;68:1356-78 PMCID:PMC6691863

[43] Bhat P.Role of Endoscopy in Primary Sclerosing Cholangitis.Clin Endosc2021;54:193-201 PMCID:PMC8039754

[44] Trikudanathan G,Njei B,Parsi MA.Diagnostic yield of bile duct brushings for cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis.Gastrointest Endosc2014;79:783-9

[45] Navaneethan U,Venkatesh PG,Parsi MA.Fluorescence in situ hybridization for diagnosis of cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis.Gastrointest Endosc2014;79:943-950.e3

[46] Njei B,Varadarajulu S.Systematic review with meta-analysis: endoscopic retrograde cholangiopancreatography-based modalities for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis.Aliment Pharmacol Ther2016;44:1139-51

[47] Keihanian T,Tejaswi S.Role of Endoscopic Retrograde Cholangiopancreatography in the Diagnosis and Management of Cholestatic Liver Diseases.Clin Liver Dis2022;26:51-67

[48] Clements O,Kim JU,Khan SA.Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis.J Hepatol2020;72:95-103

[49] Massarweh NN.Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.Cancer Control2017;24:1073274817729245 PMCID:PMC5937247

[50] Darnell A,Belmonte E.Evaluation of LI-RADS 3 category by magnetic resonance in US-detected nodules ≤ 2 cm in cirrhotic patients.Eur Radiol2021;31:4794-803

[51] Sithithaworn P,Duenngai K,Pairojkul C.Roles of liver fluke infection as risk factor for cholangiocarcinoma.J Hepatobiliary Pancreat Sci2014;21:301-8

[52] Khuntikeo N,Thinkhamrop B,Yongvanit P.A Comprehensive Public Health Conceptual Framework and Strategy to Effectively Combat Cholangiocarcinoma in Thailand.PLoS Negl Trop Dis2016;10:e0004293 PMCID:PMC4721916

[53] Khuntikeo N,Sa-Ngiamwibool P.A comparison of the proportion of early stage cholangiocarcinoma found in an ultrasound-screening program compared to walk-in patients.HPB (Oxford)2020;22:874-83

[54] Sungkasubun P,Akkarachinorate K.Ultrasound screening for cholangiocarcinoma could detect premalignant lesions and early-stage diseases with survival benefits: a population-based prospective study of 4,225 subjects in an endemic area.BMC Cancer2016;16:346 PMCID:PMC4890519

[55] Valle JW,Nervi B,Zhu AX.Biliary tract cancer.The Lancet2021;397:428-44

[56] Yang CM.Cholangiocarcinoma Evaluation via Imaging and Artificial Intelligence.Oncology2021;99:72-83

[57] Granata V,Setola SV.An update on radiomics techniques in primary liver cancers.Infect Agent Cancer2022;17:6 PMCID:PMC8897888

[58] Macias RIR,Kendall TJ.Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions.Gut2022;71:1669-83

[59] Arechederra M,Amat I.Next-generation sequencing of bile cell-free DNA for the early detection of patients with malignant biliary strictures.Gut2022;71:1141-51 PMCID:PMC9120390

[60] Moeckli B,Claasen M,Sapisochin G.Recent developments and ongoing trials in transplant oncology.Liver Int2020;40:2326-44

[61] Zhu AX,Javle MM.Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial.JAMA Oncol2021;7:1669-77 PMCID:PMC8461552

[62] Abou-alfa GK,Hollebecque A.Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.The Lancet Oncology2020;21:671-84 PMCID:PMC8461541

[63] Oh DY,Qin S.A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1.J Clin Oncol2022;40:378- 378